ImmuPharma plc (AIM:IMM)
London
· Delayed Price · Currency is GBP · Price in GBX 7.00
-0.14 (-1.96%)
At close: Mar 6, 2026
ImmuPharma Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
35.19M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arecor Therapeutics | 5.06M |
| SkinBioTherapeutics | 4.64M |
| Aptamer Group | 1.20M |
| Ondine Biomedical | 1.18M |
| hVIVO | 54.47M |
| Faron Pharmaceuticals Oy | 1.14M |
| Fusion Antibodies | 1.60M |
| Bioventix | 13.12M |
ImmuPharma News
- 18 days ago - AIM Market Roundup: Immupharma, Pebble Beach, Tungsten West - The Armchair Trader
- 3 months ago - FTSE Flat as Wall Street Gains Fail to Inspire - Investomania
- 3 months ago - AIM Market Roundup: Trellus Health, Great Western Mining, EMV Capital - The Armchair Trader
- 6 months ago - AIM Market Roundup: ImmuPharma, Rockfire Resources, Likewise - The Armchair Trader
- 6 months ago - AIM Market Roundup: Dewhurst, Metir, Tertiary Minerals - The Armchair Trader
- 6 months ago - AIM Market Roundup: ImmuPharma, N4 Pharma, Versarien - The Armchair Trader
- 7 months ago - AIM Market Roundup: Catenai, Europa Oil & Gas, Faron Pharma - The Armchair Trader
- 7 months ago - FTSE Rises as Investors Eye Tariff Deadline - Investomania